Journal of Clinical Oncology, Vol 13, 1361-1367, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Testicular lymphoma: late relapses and poor outcome despite doxorubicin- based therapy

N Touroutoglou, MA Dimopoulos, A Younes, M Hess, W Pugh, J Cox, F Cabanillas and AH Sarris
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston, USA.

PURPOSE: To determine the significance of the International Prognostic Index (IPI) score in adults with testicular lymphoma treated with doxorubicin-based regimens. PATIENTS AND METHODS: Untreated adults with testicular lymphoma who presented between 1969 and 1993 were studied. Those with Ann Arbor stages III and IV were included if they had a testicular mass at presentation. RESULTS: We identified 22 patients, 21 with intermediate-grade and one with high-grade lymphoma. All 10 patients with an IPI score < or = 1 had Ann Arbor stage I disease, whereas the 12 with an IPI score more than 1 had Ann Arbor stage II to IV disease. Complete remission (CR) was achieved in 73% of patients. At 153 months, 22% of all complete responders and 40% and 0% of those with IPI scores < or = 1 and more than 1, respectively, remained in CR (P = .01). With a median follow-up time of 113 months for survivors, the failure-free survival (FFS) rate at 153 months was 16% for all patients or 32% and 0% for those with IPI scores < or = 1 and more than 1, respectively (P = .02). The CNS or contralateral testis were involved in all patients who failed to respond to primary therapy and in 50% of those who relapsed from CR. CONCLUSION: The prognosis of patients with testicular lymphoma appears poor despite doxorubicin-based chemotherapy. On the basis of failures in the CNS and contralateral testis, we recommend prophylactic intrathecal chemotherapy and scrotal radiotherapy for all patients. Those with an IPI score < or = 1 can be treated with conventional doxorubicin-based regimens, but those with an IPI score more than 1 should be considered for investigational systemic therapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. D. Gundrum, M. A. Mathiason, D. B. Moore, and R. S. Go Primary Testicular Diffuse Large B-Cell Lymphoma: A Population-Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab J. Clin. Oncol., November 1, 2009; 27(31): 5227 - 5232. [Abstract] [Full Text] [PDF]

				R. V. Lee, C. A. Green, O. G. Negrea, S. Dodson, S. K. Farrell, J. E. Hewitt, T. Jago, C. E. Ramsey, T. Cato, E. Crawford, et al. B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP Lab Med, February 1, 2009; 40(2): 79 - 86. [Abstract] [Full Text] [PDF]

				J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF]

				R. M. Seliem, K. Chikwava, S. H. Swerdlow, R. H. Young, and J. A. Ferry Classical Hodgkin's Lymphoma Presenting as a Testicular Mass: Report of a Case International Journal of Surgical Pathology, April 1, 2007; 15(2): 207 - 212. [Abstract] [PDF]

				M. K. Tummala, P. F. Hausner, W. P. McGuire, T. Gipson, and A. Berkman CASE 1. Testis: A Sanctuary Site in Merkel Cell Carcinoma J. Clin. Oncol., February 20, 2006; 24(6): 1008 - 1009. [Full Text] [PDF]

				E. Zucca, A. Conconi, T.I. Mughal, A.H. Sarris, J.F. Seymour, U. Vitolo, R. Klasa, M. Ozsahin, G.M. Mead, M.A. Gianni, et al. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group J. Clin. Oncol., January 1, 2003; 21(1): 20 - 27. [Abstract] [Full Text] [PDF]

				S. A. Riemersma, E. S. Jordanova, R. F. J. Schop, K. Philippo, L. H. J. Looijenga, E. Schuuring, and P. M. Kluin Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites Blood, November 15, 2000; 96(10): 3569 - 3577. [Abstract] [Full Text] [PDF]

				C. Tondini, A. J.M. Ferreri, L. Siracusano, P. Valagussa, R. Giardini, I. Rampinelli, and G. Bonadonna Diffuse Large-Cell Lymphoma of the Testis J. Clin. Oncol., September 1, 1999; 17(9): 2854 - 2854. [Abstract] [Full Text] [PDF]

				K. van Besien, C. S. Ha, S. Murphy, P. McLaughlin, A. Rodriguez, K. Amin, A. Forman, J. Romaguera, F. Hagemeister, A. Younes, et al. Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma Blood, February 15, 1998; 91(4): 1178 - 1184. [Abstract] [Full Text] [PDF]